Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is sold under the brand names Nitoman and Xenazine among others. On August 15, 2008, the US Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntington's disease. Although other drugs had been used "off-label", tetrabenazine was the first approved treatment for Huntington's disease in the United States. The compound has been known since the 1950s.
via Wikipedia infobox
via PubMed
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is sold under the brand names Nitoman and Xenazine among others. On August 15, 2008, the US Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntington's disease. Although other drugs had been used "off-label", tetrabenazine was the first approved treatment for Huntington's disease in the United States. The compound has been known since the 1950s.
==Medical uses== Tetrabenazine is used as a treatment, but not as a cure, for hyperkinetic disorders such as: Huntington's disease – specifically, the chorea associated with it Tourette syndrome and other tic disorders Tardive dyskinesia, a serious and sometimes irreversible side effect of long-term use of many antipsychotics, mainly typical antipsychotics Hemiballismus, spontaneous flinging limb movements due to contra-lateral subthalamic nucleus damage
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).